ClinicalTrials.gg
Status unknownNCT01079585Updated Mar 3, 2010

The Effect of 40gr Okara on Gastric Emptying

An interventional study of Nutrigal Okara - 100 in Healthy People, sponsored by Tel-Aviv Sourasky Medical Center. Status unknown at 1 site in Israel. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-03-03.

Sponsored by Tel-Aviv Sourasky Medical Center · Not applicable and Interventional

The sponsor has not verified this record recently (last verified Feb 2010), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The effect of 40gr Okara, on gastric emptying of standard meal (Muffin cake)

Read the detailed description

This trail will be a single blinded, cross-over design. The study population will include 10 subjects. The patients will be randomly assigned to receive one of two Muffin cakes, with or without 40 grams Okara on three occasions (three visits). In two visits the subject will receive a Muffin cake with 40 grams Okara (but with similar caloric value), and in one visit a Muffin cake without Okara.

Postprandial gastric emptying time will be measured for each subject, by 13C Breath Test.

Okara is a natural water extracted food grade soy product, contains approximately 35% protein (mfb), and about 43% of dietary fibers.

02

Conditions studied

  • Healthy People
03

In context

Lead sponsor

Tel-Aviv Sourasky Medical Center is the lead sponsor of 553 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • Age 20-65 years old
  • Written Informed Consent

Exclusion criteria

Exclusion Criteria:

  • History of gastro-intestinal surgery
  • On medication that may influence gastric emptying, or medication for weight loss
  • Patient on PPI treatment, H2 Blockers or medication for weight loss
  • Known allergies to soy
  • Pregnancy or breast-feeding
  • Smoking
  • Athletes
  • Metabolic syndrome or diabetes mellitus
  • Family history of metabolic syndrome or diabetes mellitus
  • Weight loss > 2 kg during two months before the study
05

Study design

Phase
Not applicable
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single
Enrollment
10 participants (estimated)

Interventions

  • Dietary supplementNutrigal Okara - 100
06

What researchers measure

Primary outcomes

  1. To investigate the influence of 40 gram Okara on gastric emptying

07

Study locations

1 site
  • Tel Aviv Medical Center
    Tel Aviv, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01079585
Collaborators
Nutrigal LTD
First posted
Mar 3, 2010
Start date
Mar 2010
Primary completion
Oct 2010 (estimated)
Completion
Dec 2010 (estimated)
Last update
Mar 3, 2010

Study contacts

Nachum Vaisman, Prof'
Contact
vaisman@tasmc.health.gov.il
009-972-3-6974807
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion